Quotes 5-day view Delayed Nasdaq
05/16/2022
05/17/2022
05/18/2022
05/19/2022
05/20/2022
Date
254.17(c)
261.84(c)
252.35(c)
255.45(c)
258.59(c)
Last
1 558 246
1 566 842
1 396 975
1 448 836
1 552 342
Volume
+3.02%
+3.02%
-3.62%
+1.23%
+1.23%
Change
Estimated financial data (e) (USD)
Sales 2022
8 585 M
-
-
Net income 2022
3 253 M
-
-
Net cash position 2022
10 823 M
-
-
P/E ratio 2022
20,5x
Yield 2022
-
Sales 2023
9 226 M
-
-
Net income 2023
3 558 M
-
-
Net cash position 2023
14 777 M
-
-
P/E ratio 2023
18,7x
Yield 2023
-
Capitalization
66 136 M
66 136 M
-
EV / Sales 2022
6,44x
EV / Sales 2023
5,57x
Nbr of Employees
3 900
Free-Float
99,6%
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales break down by type of income as follows:
- income from sales of products (99.9%);
- royalties and income from partnership, research, and development agreements (0.1%).
Net sales are distributed...
Ratings of Vertex Pharmaceuticals
All news about VERTEX PHARMACEUTICALS
News in other languages on VERTEX PHARMACEUTICALS
Analyst Recommendations on VERTEX PHARMACEUTICALS
PUMP / DUMP #13 : This week's gainers and losers
Chart VERTEX PHARMACEUTICALS
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends VERTEX PHARMACEUTICALS
Short Term Mid-Term Long Term Trends Bearish Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
258,59 $
Average target price
294,18 $
Spread / Average Target
13,8%
Please enable JavaScript in your browser's settings to use dynamic charts.